In March 2018 BioViva USA Inc (BioViva) announced an exclusive collaboration with Integrated Health Systems Ltd (IHS). While IHS gives patients access to consensual gene and cell therapies worldwide, BioViva examines the data of their patients. Today’s investors are wary that drug development may take decades, and with unknown performance in humans. This time lag makes it difficult for  small companies to stay in business while waiting for funding. To solve the problem of efficient translation of medicine, IHS helps patients in need to get access to treatments, while BioViva has built a platform to obtain accurate patient data, and help investors know where to put their money.

BioViva’s platform for advanced gene and cell  therapeutics connects researchers with medical doctors to collect data, and indicates which of the more promising therapies in regenerative medicine are working in patients. To this end, BioViva is committed to the following:

• Bridging stakeholders with biotechnology: biotech companies will be given access to the IHS patient data and to BioViva’s platform, and shown evidence that their drugs are safe and efficient in humans.

• Accelerated path  to human trials: the IHS/BioViva platform is intended to provide biotech companies, doctors networks, and patients with fast and efficient access to each other, taking years off therapeutic development.

• Growing knowledge base: BioViva’s platform continuously collects and monitors human data, and any variations in aging biomarkers that the treatments may have incurred. BioViva utilizes the latest machine learning algorithms to validate these findings, and to find the optimal combinatorial regimens for age-reversing treatments. BioViva makes their insights available to contracted users of their platform.

• Ensuring dependability: doctor networks, biotech companies, and patients will come to depend on the benefits from BioViva platform services, and insights from their platform.

BioViva has spent many years researching how best to give patients affordable access to therapeutics, and track these patients’ data to ensure we understand what is happening after treatment.   BioViva CEO Liz Parrish states, “The ability to partake in a treatment is a human right, to be able to do it safely is medical doctors’ job, and proving whether the therapy works is the task of BioViva. This platform will expedite drug funding and therefore drug development by years. Investors need to know what drugs are working before funding lengthy trials. We are not a one treatment company. Rather, we want to be one platform for every promising biotech therapeutic.”

In that respect, BioViva is a platform company based on the principles described in this release.

 BioViva aims to be an advanced platform giving access to medicinal products. To this end BioViva is committed to the following:

• Bridging stakeholders with biotechnology

• Accelerated path  to human trials

• Growing knowledge base

• Ensuring dependability

The purpose of BioViva’s platform is to expedite the development of drugs and treatments that affect human health span. As such, BioViva has developed a comprehensive set of biomarkers of aging, including molecular, physiological, anatomical, clinical, and qualitative markers. BioViva also collaborates with clinicians, biomedical scientists, and statisticians to develop innovative protocols for adaptive clinical trials for gene and cells therapies. Finally, BioViva has built a bioinformatics pipeline to analyze the data generated from the biomarkers of aging in human trials, and validate the treatments that are effective for treating the aging process.

BioViva has recently partnered with a patient-paid-for clinical trial company Integrated Health Systems (IHS). IHS connects doctors with patients who want to take part in paid-for clinical trials. During our collaboration with IHS they will utilize our adaptive clinical trial protocols to conduct gene and cell therapy trials. All patients will undergo pre- and post testing using BioViva’s comprehensive biomarkers of aging platform. Treatment efficacy and patient well being will be assessed using our bioinformatics pipeline.

The goal of BioViva is to accelerate the development of products that will effectively, and cost-efficiently treat biological aging. Our platform is designed to provide expedited and reliable feedback to our clinical and manufacturing partners, so that they may rapidly iterate their products and services to help patients improve the quality and quantity of life.

Success for BioViva entails finding therapies that work quantitatively by reversing or slowing biological aging in humans as measured by markers of DNA methylation, as well as metabolic, physiological, anatomical, and clinical markers. In addition, we will qualitatively improve patient wellbeing by helping them achieve an optimal healthy life.

BioViva is a platform for anti-aging biotech development. BioViva is to biotech what meta-analysis is to medical research. BioViva’s platform is designed to accommodate all forms of research and development that targets the aging process in humans. We  work with biotech companies and biologic manufactures, and help them conduct accelerated adaptive clinical trials to ascertain the efficacy of their products in treating the aging process.

According to FDA drug approvals between 2004 and 2014, there is a 15 percent chance of going from Phase 1 through to FDA approvals for biologics, and a 7 percent chance of success for small molecules. This high rate of failure highlights the problems with preliminary drug testing platform. BioViva is a cost-effective solution for biotech companies to rapidly test their drugs in humans and determine where to embark on the expensive and time-consuming FDA or EMA approval process.

The biggest challenge in evaluating the efficacy of anti-aging treatments are biomarkers of aging. Currently our the best biomarkers of aging are loosely associated with biological aging especially in people aged over 50.

This is clearly the biggest problem as we cannot wait for 10 years to test every treatment. Therefore at BioViva we have designed a comprehensive biomarker of aging platform that should be able to ascertain anti-aging treatment efficacy within a couple of years.

In summary, we want to help humans live long and healthy lives, and we have built a platform to assess anyones products that can help us achieve that goal.

Liz Parrish Comment1 Likes 

Share